ADHD Stimulant Composition to Prevent Long-Term Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stimulant medications for ADHD often lead to long-term tolerance, resulting in poor adherence and persistence of treatment, despite their short-term efficacy, as they cause both acute and carry-over tolerance, undermining long-term clinical benefit.
Innovation Solution
A pharmaceutical composition comprising a first immediate-release component of a stimulant drug and a second extended-release component of a non-dopamine agonist drug, designed to maintain efficacy without accumulating tolerance, administered in a single unit dosage form on a once-daily basis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If stimulant medication is administered continuously for long-term ADHD treatment, then short-term efficacy is maintained, but tolerance accumulates and undermines long-term clinical benefit
Solution Approach 1:
The patent implements periodic action by administering the stimulant medication only on days when ADHD symptoms require treatment, rather than continuous daily administration. This intermittent dosing schedule allows the body to reset tolerance levels between treatment days, maintaining long-term efficacy while preserving short-term therapeutic benefits. The system includes a controller that monitors symptom severity and activates medication delivery only when threshold criteria are met.
Solution Approach 2:
The patent applies dynamics by making the medication delivery system adaptive and responsive to changing physiological states. The controller continuously monitors ADHD symptoms and adjusts medication administration based on real-time feedback, creating a dynamic treatment regimen that optimizes efficacy while minimizing tolerance accumulation. This dynamic approach allows the treatment intensity to vary according to actual need rather than following a fixed schedule.
2Reliability
If stimulant medication is administered frequently to maintain therapeutic levels, then symptom control is improved, but carry-over tolerance accumulates and reduces effectiveness
Solution Approach 1:
The system uses periodic action to interrupt continuous stimulant exposure by allowing drug-free intervals between treatment days. This periodic administration pattern prevents carry-over tolerance from accumulating because the body has sufficient time to reset receptor sensitivity between dosing events. The controller determines optimal intervals based on symptom monitoring, ensuring symptom control while avoiding tolerance buildup.
Solution Approach 2:
The patent applies preliminary anti-action by using non-stimulant medication or placebo administration on alternate days to counteract the development of tolerance to the stimulant. This alternating regimen preemptively addresses tolerance accumulation by introducing days without stimulant exposure, thereby preserving the stimulant's effectiveness for when it is actually needed.
3Speed
If immediate-release stimulant medication is used to achieve rapid symptom relief, then onset of action is fast, but duration of effect is short requiring multiple administrations
Solution Approach 1:
The patent combines immediate-release and extended-release stimulant medications into a single composite formulation. The immediate-release component provides rapid onset of action for quick symptom relief, while the extended-release component maintains therapeutic levels throughout the day, eliminating the need for multiple administrations. This merged formulation delivers both fast action and prolonged duration in one dosage form.
Solution Approach 2:
The medication system uses composite materials by formulating a single dosage unit containing both immediate-release and extended-release stimulant components. The immediate-release portion dissolves quickly to provide rapid symptom relief, while the extended-release portion gradually releases medication to sustain therapeutic effects. This composite approach resolves the contradiction between fast onset and long duration.
Data Source
AI summary
It is proposed that dissipation of relative benefit during long-term treatment is due to long-term tolerance to stimulant medications. To improve adherence and persistence of medication use, it is advantageous to develop medications that are not undermined by long-term tolerance. Disclosed herein in certain implementations are methods for the prevention of accumulated tolerance to stimulant medication for the treatment of ADHD based on two principles: (a) retaining the initial immediate-release component of controlled-release formulations, and (b) replacing the subsequent sustained-release component (i.e., an ascending delivery of stimulant medication to counteract acute tolerance) with a controlled-release component designed to prevent carry-over effects on background tonic dopamine.